Silence Therapeutics ( (SLN) ) has shared an update.
Silence Therapeutics reported its financial results for the year ending December 31, 2024, highlighting strong clinical execution and pipeline advancements. The company plans to prioritize investment in siRNA programs targeting rare conditions, with a focus on the divesiran program for polycythemia vera (PV) and the zerlasiran program for cardiovascular disease. Silence ended the year with $147 million in cash, and its decision to delay the zerlasiran Phase 3 study until a partner is secured extends its cash runway into 2027. The company received positive regulatory feedback for the zerlasiran study design and anticipates full enrollment in the SANRECO Phase 2 study of divesiran by the end of 2025.
More about Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company focused on developing precision engineered medicines using proprietary siRNA technology. The company leverages its mRNAi GOLD platform to target and silence disease-associated genes, particularly in the liver, with a focus on cardiovascular disease, hematology, and rare diseases.
YTD Price Performance: -33.66%
Average Trading Volume: 429,313
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $222.6M
See more data about SLN stock on TipRanks’ Stock Analysis page.